+86-28-82633987sales@biopurify.com
Batch Search
Alternate Text
Home > Product Category > Compound Types > Triterpenoids

3-Acetyl-11-keto-beta-boswellic Acid

CAS No.:67416-61-9

3-Acetyl-11-keto-beta-boswellic Acid
Catalogue No.: BP3057
Formula: C32H48O5
Mol Weight: 512.731
Botanical Source: Olibanum
Contacts
+86-28-82633860  +86-18080483897
 
Email: sales@biopurify.com biopurify@gmail.com

3-Acetyl-11-keto-beta-boswellic Acid

CAS No.:67416-61-9

3-Acetyl-11-keto-beta-boswellic Acid
Catalogue No.: BP3057
Formula: C32H48O5
Mol Weight: 512.731
Botanical Source: Olibanum
Contacts
+86-28-82633860  +86-18080483897
 
Email: sales@biopurify.com biopurify@gmail.com
Over 15 years of industry experience in phytochemicals from R&D(reference substances) to Industrialization, please feel free to contact us!

Product name: 3-Acetyl-11-keto-beta-boswellic acid
Synonym name: AKBA; AKBBA
Catalogue No.: BP3057
Cas No.: 67416-61-9
Formula: C32H48O5
Mol Weight: 512.731
Botanical Source:
Physical Description: Powder
Type of Compound: Triterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
The product could be supplied from milligrams to grams. Inquire for bulk scale.
We provide solution to improve the water-solubility of compounds, thereby facilitating the variety of activity tests and clinic uses.

For Reference Standard and R&D, Not for Human Use Directly.


Description:

3-O-Acetyl-11-keto-beta-boswellic acid inhibits 5-lipoxygenase product formation with an IC(50) of 1.5 m muM.

 

References:

Toxicol Mech Methods. 2006;16(4):199-226.    

Safety and Toxicological Evaluation of a Novel, Standardized 3-O-Acetyl-11-keto-beta-Boswellic Acid (AKBA)-Enriched Boswellia serrata Extract (5-Loxin(R)).    

The novel anti-inflammatory properties of the gum resin derived from Boswellia serrata, also known as Salai guggal in Ayurvedic medicine, are well recognized and highly recommended for human consumption. The active constituents of the gum resin are boswellic acids (BAs). Among the BAs, 3-O-Acetyl-11-keto-beta-boswellic acid potently inhibits 5-lipoxygenase product formation with an IC(50) of 1.5 m muM. 

CONCLUSIONS:

We developed a novel Boswellia serrata extract (5-Loxin(R)) enriched with 30% 3-O-Acetyl-11-keto-beta-boswellic acid (US Patent 2004/0073060A1).    

Biomed Chromatogr. 2014 Oct;28(10):1402-8.    

Comparative pharmacokinetic study of two boswellic acids in normal and arthritic rat plasma after oral administration of Boswellia serrata extract or Huo Luo Xiao Ling Dan by LC-MS.    

11-keto-β-boswellic acid and 3-O-Acetyl-11-keto-beta-boswellic acid following oral administration of HLXLD or Boswellia serrata extract alone in normal and arthritic rats. 

METHODS AND RESULTS:

An LC-MS method was developed and validated for the determination of 11-keto-β-boswellic acid and 3-O-Acetyl-11-keto-beta-boswellic acid in the comparative pharmacokinetic study. The results showed that there were significant differences in pharmacokinetic parameters between normal and arthritic groups. Interestingly, the absorptions of two boswellic acids were significantly higher in HLXLD than Boswellia serrata extract alone, indicating the synergistic effect of other herbal ingredients in HLXLD. 

CONCLUSIONS:

This comparative pharmacokinetic study provided direct evidence supporting the notion that the efficacy of a complex mixture such as HLXLD is better than that of single components in treating human diseases.